Durvalumab Approved For Resectable Upper Gastrointestinal Cancers
Durvalumab Approved For Resectable Upper Gastrointestinal Cancers

Yelena Janjigian, MD, Rahul Gosain, MD, MBA, Rohit Gosain, MD

FDA Approval of Cabozantinib in Neuroendocrine Tumors
FDA Approval of Cabozantinib in Neuroendocrine Tumors

Aman Chauhan, MD